Contact us

Introduction

In many emerging markets — especially India — traditional pharmaceutical marketing relies heavily on in-person medical representative (MR) visits to doctors. While this model dominated for decades, substantial evidence now shows it often fails to deliver efficient, consistent doctor engagement — especially in remote, non-metro regions. This results in major portions of field marketing budgets being wasted or under-utilized across regions that represent significant prescription potential.

1. Field Force Efficiency Is Shockingly Low

Despite large investments in field personnel, studies show that field sales teams often operate at only 60–70% efficiency, meaning a large percentage of planned doctor interactions either don’t happen or fail to produce meaningful engagements. Visit frequency adherence often drops to 30–40%, especially outside major cities, resulting in suboptimal doctor coverage and weak ROI on manpower. ETPharma.com

2. Geography Makes Traditional Visits Costly and Inefficient

In rural and semi-urban India, geographic distance and infrastructure limitations make field visits extremely resource-intensive. Pharma sales teams can travel hundreds of kilometers a day to meet just a handful of doctors and retailers. For example, one team reported travelling ~200–300 km daily to cover 9–10 doctors and 4–5 retailers. The Economic Times

This means:

All these dilute the effectiveness of field marketing spend.

3. Doctor Engagement Has Changed Faster Than Pharma Strategy

The era of doctors having ample time for MR visits is over. Research indicates doctors now spend very limited face-to-face time with reps — often seconds to a few minutes — severely reducing the value of each interaction. Hexaware Technologies

Furthermore, digital and non-personal channels (email, webinars, online content) now make up a larger share of physician engagement than in-person rep visits. In one industry survey, non-personal marketing channels accounted for more than 50% of doctor outreach — surpassing traditional rep interactions. Fierce Pharma

4. Fragmented Data and Marketing Silos Hurt Coordination

A common operational problem is fragmented data systems within pharma organizations. Marketing, CRM, medical, compliance, and event systems rarely integrate, creating blind spots in tracking doctor interactions and campaign performance. Teams have partial views of engagements — leading to duplicated efforts and wasted budget on activities that don’t drive real outcomes. Valuebound

When pharma operates “blind,” it often continues funding legacy channels that look active on paper but don’t materially engage remote doctors.

5. Doctors Are Less Available and More Selective

Multiple reports highlight that many doctors — especially in non-metro areas — either prefer digital communication or have limited availability for rep visits. The pandemic further accelerated this shift, with doctors increasingly favoring remote/virtual interactions over routine in-person visits. Fierce Pharma

This means pharma companies that rely mainly on field reps without embracing omnichannel engagement are missing large portions of doctor attention — especially in areas where travel and time costs are highest.

6. Compliance and Regulatory Pressures Redirect Spend

Regulatory scrutiny around interactions between healthcare professionals and pharma companies is increasing globally. New guidelines and transparency norms mean that older methods of incentivizing or engaging doctors are either restricted or require elaborate tracking. This forces companies to spend more on compliance management and less on effective outreach — reducing actual field ROI. Bessemer Venture Partners

Conclusion

The traditional pharma field force model is expensive and fundamentally limited:

Collectively, these factors explain why an estimated 60–70% or more of pharma field budgets fail to deliver targeted engagement with remote doctors. The result is high spend with low impact, particularly in regions that represent significant prescription growth opportunity

What This Means for Pharma Marketers

To unlock true reach and ROI:
✅ Integrate digital engagement channels (remote detailing, webinars, WhatsApp content, mobile platforms)
✅ Invest in data unification and CRM analytics
✅ Optimize field resource allocation using real-time performance data
✅ Build omnichannel doctor engagement strategies

The future of pharma marketing is data-driven, digital-first, and optimized for real interactions — not activities. If you’re still relying on legacy field force models without measurement and digital outreach, most of your budget may already be dead weight.